Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Current Deferred Revenue (2016 - 2018)

Immucell (ICCC) has disclosed Current Deferred Revenue for 8 consecutive years, with $24100.0 as the latest value for Q3 2018.

  • For the quarter ending Q3 2018, Current Deferred Revenue changed N/A year-over-year to $24100.0, compared with a TTM value of $24100.0 through Sep 2018, changed N/A, and an annual FY2017 reading of $24100.0, down 28.82% over the prior year.
  • Current Deferred Revenue was $24100.0 for Q3 2018 at Immucell, roughly flat from $24100.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $33856.0 in Q3 2016 and bottomed at $6690.0 in Q3 2014.
  • Average Current Deferred Revenue over 5 years is $20464.7, with a median of $24100.0 recorded in 2017.
  • Peak annual rise in Current Deferred Revenue hit 28.82% in 2017, while the deepest fall reached 28.82% in 2017.
  • Year by year, Current Deferred Revenue stood at $6690.0 in 2014, then changed by 0.0% to $6690.0 in 2015, then surged by 406.07% to $33856.0 in 2016, then fell by 28.82% to $24100.0 in 2017, then changed by 0.0% to $24100.0 in 2018.
  • Business Quant data shows Current Deferred Revenue for ICCC at $24100.0 in Q3 2018, $24100.0 in Q2 2018, and $24100.0 in Q1 2018.